Dacarbazine

DB00851ApprovedInvestigationalSmall moleculeAlkylating Drugs

Dacarbazine is an antineoplastic agent used to treat malignant melanoma and Hodgkin's disease. It has significant activity against melanomas.

Mechanism: The mechanism of action is not known, but appears to exert cytotoxic effects via its action as an alkylating agent. Other theories include DNA synthesis inhibition by its action as a purine analog, and interaction with SH groups. Dacarbazine is not cell cycle-phase specific.
Curator reviewed
Primary indication: For the treatment of metastatic malignant melanoma.Curator reviewed · 6 structured indications
Formula / weight: C₆H₁₀N₆O · 182.187 g/mol (avg)
First approval: Canada, 2017 · United States, 1998
Also known as: Biocarbazine · DTIC · ICDMT · imidazole carboxamide
Code names: HSDB 3219 · NCI-C04717 · NSC-45388 · WR-139007

Resolves to

Compound

UNII7GR28W0FJICAS4342-03-4ChEMBLCHEMBL476ChEBI177836PubChem135398738KEGGD00288

Clinical / RWD

RxNorm3098ATCL01AX04PharmGKBPA449197

Structure

InChIKeyFDKXTQMXEQVLRF-ZHACJKMWSA-NSMILESCN(C)\N=N\C1=C(N=CN1)C(N)=O

Targets

Q14181POLA2P52209PGD

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,604Drug interactionsStructured to mechanism, not free text

164Clinical trialsPhase, status and sponsor resolved per trial

6Structured indicationsCondition, population, route and combination as fields, not prose

60Marketed productsAcross 10 countries and 31 labellers

1ATC codeIncluding every combination product, plus 21 drug categories

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dacarbazine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In